⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21981571 | 0.97 | — | — | |
| SCHEMBL23812322 | 0.76 | — | — | |
| SCHEMBL99224 | 0.73 | L3MBTL1 (0.32) | — | |
| SCHEMBL147208 | 0.72 | — | — | |
| SCHEMBL28180840 | 0.72 | — | — | |
| SCHEMBL19231405 | 0.72 | — | — | |
| SCHEMBL10473136 | 0.72 | KMT2A (0.34) | — | |
| SCHEMBL23400742 | 0.70 | ADORA2A (0.44) | — | |
| SCHEMBL23160604 | 0.69 | BAZ2B (0.41) | — | |
| SCHEMBL23400839 | 0.69 | NPC1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008060378-A2 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| CN-101107243-A | Substituted triazole derivatives as oxytocin antagonists | PFIZER (GB) | 2008-01-16 | — | — | CN | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007096362-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | TRIGEN LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |